We are live on ! Find out more
AA

AlphaCentric Advisors Portfolio holdings

AUM $118M
This Fund
S&P 500
This Quarter Est. Return
+6.03%
1 Year Est. Return
3 Year Est. Return
5 Year Est. Return
10 Year Est. Return
AUM
$240M
AUM Growth
+$33.2M
Cap. Flow
+$24.9M
Cap. Flow %
10.4%
Top 10 Hldgs %
83.63%
Holding
243
New
78
Increased
59
Reduced
41
Closed
38

Sector Composition

Rank Sector Weight
1 Real Estate 16.47%
2 Healthcare 9.94%
3 Technology 2.63%
4 Industrials 1.15%
5 Materials 0.74%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
ANAB icon
151
AnaptysBio
ANAB
$1.6B
$86K 0.04%
+4,000
New +$97.1K
WIP icon
152
State Street SPDR FTSE International Government Inflation-Protected Bond ETF
WIP
$479M
$83K 0.03%
1,412
-2
-0.1% -$112
SCHP icon
153
Schwab US TIPS ETF
SCHP
$16.3B
$81K 0.03%
2,600
+66
+3% +$2.03K
FLRN icon
154
State Street SPDR Bloomberg Investment Grade Floating Rate ETF
FLRN
$3.11B
$80K 0.03%
2,614
+49
+2% +$1.5K
IGSB icon
155
iShares 1-5 Year Investment Grade Corporate Bond ETF
IGSB
$22.8B
$80K 0.03%
1,451
+27
+2% +$1.48K
LQD icon
156
iShares iBoxx $ Investment Grade Corporate Bond ETF
LQD
$34.7B
$80K 0.03%
578
-1
-0.2% -$136
MUB icon
157
iShares National Muni Bond ETF
MUB
$45.1B
$80K 0.03%
685
-212
-24% -$24.6K
GSK icon
158
GSK
GSK
$103B
$77K 0.03%
1,680
+1,520
+950% +$69.8K
NKTR icon
159
Nektar Therapeutics
NKTR
$2.39B
$77K 0.03%
+300
New +$77.5K
MORF
160
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$75K 0.03%
+2,250
New +$66.5K
ORTX
161
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
$73K 0.03%
1,700
+1,410
+486% +$63.1K
HZNP
162
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$73K 0.03%
1,000
+425
+74% +$31.6K
RVNC
163
DELISTED
Revance Therapeutics, Inc.
RVNC
$71K 0.03%
+2,500
New +$64.8K
TCRR
164
DELISTED
TCR2 Therapeutics Inc. Common Stock
TCRR
$70K 0.03%
2,275
+375
+20% +$9.48K
DVAX
165
DELISTED
Dynavax Technologies
DVAX
$65K 0.03%
14,500
+13,900
+2,317% +$62.9K
MNST icon
166
Monster Beverage
MNST
$91.4B
$65K 0.03%
+1,410
New +$59.2K
A icon
167
Agilent Technologies
A
$39.1B
$64K 0.03%
+536
New +$59.3K
AMZN icon
168
Amazon
AMZN
$2.5T
$62K 0.03%
380
-20
-5% -$3.19K
IDXX icon
169
Idexx Laboratories
IDXX
$42.9B
$62K 0.03%
+124
New +$55.5K
CLDX icon
170
Celldex Therapeutics
CLDX
$2.77B
$61K 0.03%
3,500
RVTY icon
171
Revvity
RVTY
$12.3B
$61K 0.03%
+425
New +$56.6K
TYL icon
172
Tyler Technologies
TYL
$12.2B
$61K 0.03%
+140
New +$57.8K
CHTR icon
173
Charter Communications
CHTR
$14.7B
$60K 0.03%
90
-9
-9% -$5.73K
WST icon
174
West Pharmaceutical
WST
$23.1B
$56K 0.02%
+199
New +$55.8K
COST icon
175
Costco
COST
$415B
$55K 0.02%
146
-12
-8% -$4.48K

Similar funds

AlphaCentric Advisors's Q4 2020 Portfolio in Review

As of Q4 2020, AlphaCentric Advisors held 243 positions worth $240M, up 16% from $207M the previous quarter. Its ten largest holdings account for 84% of the portfolio.

AlphaCentric Advisors deployed $24.9M of net new capital in Q4 2020, opening 78 new positions and adding to 59 existing holdings. Its largest new stake was Nano Dimension: 125,000 shares worth $1.14M.

By sector, the portfolio is most concentrated in Real Estate at 16% of assets, down from 17% a quarter earlier, followed by Healthcare and Technology.

On the sell side, the largest reduction was iShares 1-3 Year Treasury Bond ETF, an estimated $3.98M trimmed.

  • AlphaCentric Advisors's largest Q4 2020 buy was Nano Dimension: 125,000 shares worth $1.14M.
  • AlphaCentric Advisors added most to Vanguard Mortgage-Backed Securities ETF in Q4 2020, an estimated $14.9M increase.
  • AlphaCentric Advisors's biggest Q4 2020 reduction was iShares 1-3 Year Treasury Bond ETF, cutting an estimated $3.98M.
  • AlphaCentric Advisors fully exited FLIR Systems, Inc. (DE) Common Stock in Q4 2020, selling an estimated $896K.
  • AlphaCentric Advisors's ten largest holdings make up 84% of its $240M portfolio in Q4 2020.
  • AlphaCentric Advisors opened 78 new positions and closed 38 in Q4 2020.
  • AlphaCentric Advisors's portfolio value rose 16% quarter-over-quarter to $240M.

Based on AlphaCentric Advisors's 13F filing for Q4 2020, filed 11 Mar 2022.